Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year High on Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares reached a new 52-week high during mid-day trading on Wednesday after Wells Fargo & Company raised their price target on the stock from $235.00 to $250.00. Wells Fargo & Company currently has an overweight rating on the stock. Jazz Pharmaceuticals traded as high as $192.66 and last traded at $192.7220, with a volume of 1408011 shares changing hands. The stock had previously closed at $173.83.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. Bank of America lifted their target price on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. UBS Group restated a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Fourteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $208.53.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the transaction, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,200,454.40. This trade represents a 39.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is owned by insiders.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of JAZZ. Farther Finance Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares during the period. Hilltop National Bank bought a new position in Jazz Pharmaceuticals in the fourth quarter worth about $36,000. Hantz Financial Services Inc. boosted its stake in Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares during the period. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Finally, Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $40,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The company has a fifty day moving average price of $168.08 and a 200 day moving average price of $150.27. The company has a market capitalization of $11.56 billion, a P/E ratio of -31.40, a price-to-earnings-growth ratio of 0.93 and a beta of 0.26.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.